MedTrace Logo

the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease

NCT06776419 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2025-04-08

No results posted yet for this study

Summary

The overall objective of this study is to investigate Fabry-related cardiomyopathy and the use of native T1-mapping, coronary microvascular function, cardiac inflammation, and cardiac injury in an effort to improve the ability to detect disease. The study aims to achieve this by:

1. Investigating the association between cardiac inflammation, fibrosis, and injury against the distribution and degree of microvascular disease in patients with Fabry disease with and without left ventricular hypertrophy (LVH) using cardiac magnetic resonance (CMR) imaging and 82Rubidium Positron emission tomography and computer tomography (82Rb-PET/CT).
2. Using an extensive, in-depth biomarker blood panel to investigate the pathological pathways associated with Fabry disease and Fabry-related cardiomyopathy.

Conditions

Interventions

DIAGNOSTIC_TEST

Cardiac Magnetic Ressonance Imaging

CMR-protocol with gadolinium contrast

DIAGNOSTIC_TEST

82Rubidium-positron emission tomography and computer-tomography

cardiac Rb-PET protocol

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Caroline Michaela Kistorp

    lead OTHER

Principal Investigators

  • Caroline Kistorp, Professor · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2030-12-01
Completion
2031-06-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06776419 on ClinicalTrials.gov